中低收入国家预防心血管疾病的抗高血压和他汀类药物综合治疗方案。

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Global Heart Pub Date : 2024-12-10 eCollection Date: 2024-01-01 DOI:10.5334/gh.1376

Andrew E Moran, Obehi Aimiosior, Reena Gupta, Anupam Pathni, Swagata Kumar Sahoo, Girma Dessie, Kufor Osi, Xiulei Zhang, Bolanle Banigbe, Renu Garg, Thomas R Frieden

{"title":"中低收入国家预防心血管疾病的抗高血压和他汀类药物综合治疗方案。","authors":"Andrew E Moran, Obehi Aimiosior, Reena Gupta, Anupam Pathni, Swagata Kumar Sahoo, Girma Dessie, Kufor Osi, Xiulei Zhang, Bolanle Banigbe, Renu Garg, Thomas R Frieden","doi":"10.5334/gh.1376","DOIUrl":null,"url":null,"abstract":"In low- and middle-income countries where the majority of preventable cardiovascular disease deaths occur, less than 10% of eligible patients receive statins for primary cardiovascular disease prevention. Since 2017, the Global Hearts initiative has implemented simple World Health Organization (WHO) HEARTS hypertension and diabetes treatment protocols. In this editorial, we propose an approach of integrating statin treatment into existing HEARTS hypertension and diabetes protocols as a way of expanding statin coverage in low-and middle-income countries.","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"19 1","pages":"93"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639695/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrated Antihypertensive and Statin Treatment Protocols for Cardiovascular Disease Prevention in Low- and Middle-Income Countries.\",\"authors\":\"Andrew E Moran, Obehi Aimiosior, Reena Gupta, Anupam Pathni, Swagata Kumar Sahoo, Girma Dessie, Kufor Osi, Xiulei Zhang, Bolanle Banigbe, Renu Garg, Thomas R Frieden\",\"doi\":\"10.5334/gh.1376\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In low- and middle-income countries where the majority of preventable cardiovascular disease deaths occur, less than 10% of eligible patients receive statins for primary cardiovascular disease prevention. Since 2017, the Global Hearts initiative has implemented simple World Health Organization (WHO) HEARTS hypertension and diabetes treatment protocols. In this editorial, we propose an approach of integrating statin treatment into existing HEARTS hypertension and diabetes protocols as a way of expanding statin coverage in low-and middle-income countries.\",\"PeriodicalId\":56018,\"journal\":{\"name\":\"Global Heart\",\"volume\":\"19 1\",\"pages\":\"93\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639695/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Heart\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5334/gh.1376\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1376","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

在大多数可预防的心血管疾病死亡发生的中低收入国家，只有不到10%的符合条件的患者接受他汀类药物用于心血管疾病的初级预防。自 2017 年以来，全球心计划实施了简单的世界卫生组织（WHO）HEARTS 高血压和糖尿病治疗方案。在这篇社论中，我们提出了一种将他汀类药物治疗纳入现有 HEARTS 高血压和糖尿病治疗方案的方法，以此扩大他汀类药物在中低收入国家的覆盖范围。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Integrated Antihypertensive and Statin Treatment Protocols for Cardiovascular Disease Prevention in Low- and Middle-Income Countries.

In low- and middle-income countries where the majority of preventable cardiovascular disease deaths occur, less than 10% of eligible patients receive statins for primary cardiovascular disease prevention. Since 2017, the Global Hearts initiative has implemented simple World Health Organization (WHO) HEARTS hypertension and diabetes treatment protocols. In this editorial, we propose an approach of integrating statin treatment into existing HEARTS hypertension and diabetes protocols as a way of expanding statin coverage in low-and middle-income countries.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.